Zobrazeno 1 - 10
of 584
pro vyhledávání: '"FDA: Food and Drug Administration"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Combining immune checkpoint and proton pump inhibitors is widely used in cancer treatment. However, the drug-drug interactions of these substances are currently unknown. This study aimed to explore drug-drug interactions associate
Externí odkaz:
https://doaj.org/article/5fe85e835f69445692ad453ca97b9064
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatment of chr
Externí odkaz:
https://doaj.org/article/9c59153d5af146aeb7865719eb56c1fe
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Modern cancer therapeutics are increasingly targeted, bringing the promise of new and improved activity, alongside better tolerability. However, while many are indeed resulting in dramatic improvements in disease control and patient survival, short-
Externí odkaz:
https://doaj.org/article/0bbf4a7b3d594c28a1a9ebc08cffbed6
Autor:
Kimberly Chiu, Rebecca Racz, Keith Burkhart, Jeffry Florian, Kevin Ford, M. Iveth Garcia, Robert M. Geiger, Kristina E. Howard, Paula L. Hyland, Omnia A. Ismaiel, Naomi L. Kruhlak, Zhihua Li, Murali K. Matta, Kristin W. Prentice, Aanchal Shah, Lidiya Stavitskaya, Donna A. Volpe, James L. Weaver, Wendy W. Wu, Rodney Rouse, David G. Strauss
Publikováno v:
Frontiers in Medicine, Vol 9 (2023)
The U.S. Food and Drug Administration (FDA) Division of Applied Regulatory Science (DARS) moves new science into the drug review process and addresses emergent regulatory and public health questions for the Agency. By forming interdisciplinary teams,
Externí odkaz:
https://doaj.org/article/9d617856bbe343189c0a88673db07198
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/e5a0627f956e42a49988b473d2b2ea66
Autor:
Steffen Eich, Thomas Friedli, Dr.
Publikováno v:
Brazilian Journal of Operations & Production Management, Vol 18, Iss 3 (2021)
Goal: The goal of this paper is to test the possible connection between pharmaceutical manufacturing plants’ Operational Excellence implementation and regulatory inspection outcomes. Methodology: This paper uses logistic regression models on a u
Externí odkaz:
https://doaj.org/article/41a11abbad2f46b8b7b02d3208575260
Autor:
Paula Pleguezuelos-Beltrán, Patricia Gálvez-Martín, Daniel Nieto-García, Juan Antonio Marchal, Elena López-Ruiz
Publikováno v:
Digibug. Repositorio Institucional de la Universidad de Granada
instname
instname
This research was funded by Fundacion Mutua Madrilena (FMM-AP17196-2019) , the Consejeria de Economia, Conocimiento, Empresas y Universidad de la Junta de Andalucia (ERDF funds, projects B-CTS-230-UGR18, PY18-2470, A-CTS-180-UGR20, SOMM17-6109, PYC20
Autor:
Jennifer K. Carroll, Paulina Arias Hernandez, Alicia Brooks-Greisen, Juan Carlos Cardet, Jing Cui, Brianna Ericson, Maureen Fagan, Merritt L. Fajt, Victoria E. Forth, Anne L. Fuhlbrigge, Margie Lorenzi, Jacqueline Rodriguez-Louis, Nancy E. Maher, Brian K. Manning, Wilson D. Pace, Joel B. Shields, Elliot Israel
Publikováno v:
Journal of the National Medical Association
Purpose To describe the socioeconomic and healthcare-related effects of the COVID-19 pandemic, and willingness to receive a free COVID-19 vaccine, among African American/Black (AA/B) and Hispanic/Latinx (H/L) adults with asthma currently enrolled in
Autor:
Stephen J. Thomas, John L. Perez, Stephen P. Lockhart, Subramanian Hariharan, Nicholas Kitchin, Ruth Bailey, Katherine Liau, Eleni Lagkadinou, Özlem Türeci, Ugur Şahin, Xia Xu, Kenneth Koury, Samuel S. Dychter, Claire Lu, Teresa C. Gentile, William C. Gruber
Publikováno v:
Vaccine
Introduction Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials excluded participants with